Global Insulin Pens Market Size, Share, Opportunities And Trends By Types (Disposable Insulin Pens, Reusable Insulin Pens), By Indication (Type I Diabetes, Type II Diabetes, Gestational Diabetes), By End Users (Hospitals And Clinics, Ambulatory Care Settings, Home Care Settings) And Geography - Forecasts From 2019 To 2024

  • Published : Mar 2020
  • Report Code : KSI061612025
  • Pages : 96

The global Insulin Pens market is expected to reach $XX billion by 2023 from $XX billion in 2017 growing at a CAGR of XX%. Insulin pens are infusion devices used to inject insulin by diabetic patients. Insulin pens offer easier administration of insulin and is more accurate, and in a convenient way than the traditional vial and syringe method. Low cost of these pens have also increased the affordability among all he classes of the people. They are portable and deliver accurate doses of insulin thus avoiding any wastage of the medication during the use. The insulin pen market is expected to significant growth during the given time frame. The growth in the market may be attributed to the rising prevalence of diabetes across the globe. Technological advancements in the insulin pens will also positively impact the market during the given forecast period. Ease of administration provided by the insulin pens along with accuracy will also fuel the growth of the market. However, its inability to mix and used with two different types of insulin might hamper the growth of the market during the given time frame.

This research study examines the current market trends related to the demand, supply, and sales, in addition to the recent developments. Major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented in each of the geographical region. Further, the overall regulatory framework of the market has been exhaustively covered to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Identification of key industry players in the industry and their revenue contribution to the overall business or relevant segment aligned to the study have been covered as a part of competitive intelligence done through extensive secondary research. Various studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research. Both bottom-up and top down approaches have been utilized to determine the market size of the overall market and key segments. The values obtained are correlated with the primary inputs of the key stakeholders in the global Insulin Pens market value chain. Last step involves complete market engineering which includes analysing the data from different sources and existing proprietary datasets while using various data triangulation methods for market breakdown and forecasting.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the global Insulin Pens market.

Major industry players profiled as part of the report are Biocon, Sanofi and Novo Nordisk among others.


By Types

Disposable Insulin Pens

Reusable Insulin Pens

By Indication

Type I Diabetes

Type II Diabetes

Gestational Diabetes

By End Users

Hospitals and Clinics

Ambulatory Care Settings

Home Care Settings

By Geography

North America

United States



South America





United Kingdom




Middle East and Africa

Saudi Arabia




Asia Pacific




South Korea


Key questions answered by the report

What will be the global Insulin Pens market size from 2018 to 2023?

How are the major drivers and restraints affecting the global Insulin Pens market growth and the opportunities which exist for key vendors?

Which segment and region will drive or lead the market growth and why?

A comprehensive analysis of competitive landscape and key market participants’ behaviour

Key strategies being adopted by vendors, with in-depth analysis along with their impact on competition and market growth

1. Introduction
1.1. Market Definition
1.2. Scope of the Study
1.3. Currency
1.4. Assumptions
1.5. Base, and Forecast Years Timeline
2. Research Methodology
2.1. Research Design
2.2. Secondary Sources
2.3. Validation
3. Key Findings of the Study
4. Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunities and Market Trends
4.4. Market Segmentation
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
4.6. Industry Value Chain Analysis
4.7. Industry Regulations
4.8. Scenario Analysis
5. Global Insulin Pens Market Forecast by Type  
5.1. Disposable Insulin Pens
5.2. Reusable Insulin Pens
6. Global Insulin Pens Market Forecast by Indication
6.1. Type I Diabetes
6.2. Type II Diabetes
6.3. Gestational Diabetes
7. Global Insulin Pens Market Forecast by End Users
7.1. Hospitals and Clinics
7.2. Ambulatory Care Settings
7.3. Home Care Settings
8. Global Insulin Pens Market Forecast by Geography 
8.1. North America
8.1.1. The U.S
8.1.2. Canada
8.1.3. Mexico
8.1.4. Others
8.2. South America
8.2.1. Brazil 
8.2.2. Argentina
8.2.3. Others
8.3. Europe
8.3.1. U.K.
8.3.2. France
8.3.3. Germany
8.3.4. Italy
8.3.5. Others
8.4. Middle East and Africa
8.4.1. Saudi Arabia
8.4.2. UAE
8.4.3. Israel
8.4.4. Others
8.5. Asia Pacific 
8.5.1. China
8.5.2. India
8.5.3. Australia
8.5.4. South Korea
8.5.5. Others 
9. Competitive intelligence
9.1. Market Share Analysis
9.2. Strategies of Key Players
9.3. Recent Investments and Deals
10. Company Profiles
10.1. Novo Nordisk
10.1.1. Overview 
10.1.2. Financials
10.1.3. Product and Services 
10.1.4. Recent Developments
10.2. Smiths Group plc.
10.2.1. Overview 
10.2.2. Financials
10.2.3. Product and Services 
10.2.4. Recent Developments
10.3. Eli Lilly and Company
10.3.1. Overview 
10.3.2. Financials
10.3.3. Product and Services 
10.3.4. Recent Developments
10.4. Companion Medical
10.4.1. Overview 
10.4.2. Financials
10.4.3. Product and Services 
10.4.4. Recent Developments
10.5. Insulcloud SL
10.5.1. Overview 
10.5.2. Financials
10.5.3. Product and Services 
10.5.4. Recent Developments
10.6. Sanofi
10.6.1. Overview 
10.6.2. Financials
10.6.3. Product and Services 
10.6.4. Recent Developments
10.7. Diamesco Co., Ltd.
10.7.1. Overview 
10.7.2. Financials
10.7.3. Product and Services 
10.7.4. Recent Developments
10.8. Emperra GmbH E-Health Technologies
10.8.1. Overview 
10.8.2. Financials
10.8.3. Product and Services 
10.8.4. Recent Developments
10.9. Owen Mumford Ltd
10.9.1. Overview 
10.9.2. Financials
10.9.3. Product and Services 
10.9.4. Recent Developments
10.10. Biocon
10.10.1. Overview 
10.10.2. Financials
10.10.3. Product and Services 
10.10.4. Recent Developments

Novo Nordisk

Smiths Group plc.

Eli Lilly and Company

Companion Medical

Insulcloud SL


Diamesco Co., Ltd.

Emperra GmbH E-Health Technologies

Owen Mumford Ltd